$VIR
Vir Biotechnology, Inc. Stock $vir

$vir Overview Financials Valuation SEC Filings Company Website

2024 Q2 Form 10-Q Financial Statement

#000162828024020299 Filed on May 03, 2024

Income Statement

Concept	2024 Q2	2024 Q1
Revenue	$3.075M	$56.38M
YoY Change	-19.02%	-10.45%
Cost Of Revenue	$52.00K	$59.00K
YoY Change	136.36%	-96.91%
Gross Profit	$3.023M	$56.32M
YoY Change	-19.92%	-7.75%
Gross Profit Margin	98.31%	99.9%
Selling, General & Admin	$30.27M	$36.27M
YoY Change	-35.74%	-22.46%
% of Gross Profit	1001.16%	64.41%
Research & Development	$105.1M	$100.1M
YoY Change	-38.84%	-36.49%
% of Gross Profit	3477.11%	177.79%
Depreciation & Amortization	$4.200M	$4.517M
YoY Change	-8.7%	-17.87%
% of Gross Profit	138.93%	8.02%
Operating Expenses	$135.4M	$136.4M
YoY Change	-38.17%	-33.28%
Operating Profit	-$158.6M	-$80.08M
YoY Change	-26.28%	-44.14%
Interest Expense	$19.28M	$15.37M
YoY Change	7.5%	87.32%
% of Operating Profit
Other Income/Expense, Net	$18.74M	$15.08M
YoY Change	6.7%	8140.98%
Pretax Income	-$139.9M	-$65.00M
YoY Change	-29.21%	-54.61%
Income Tax	-$1.512M	$276.0K
% Of Pretax Income
Net Earnings	-$138.4M	-$65.28M
YoY Change	-28.95%	-53.69%
Net Earnings / Revenue	-4500.1%	-115.79%
Basic Earnings Per Share	-$1.02	-$0.48
Diluted Earnings Per Share	-$1.02	-$0.48
COMMON SHARES
Basic Shares Outstanding	136.1M shares	135.0M shares
Diluted Shares Outstanding	136.2M shares	135.3M shares

Balance Sheet

Concept	2024 Q2	2024 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$1.151B	$1.150B
YoY Change	-37.69%	-48.9%
Cash & Equivalents	$296.9M	$160.7M
Short-Term Investments	$854.2M	$989.1M
Other Short-Term Assets	$1.000M	$4.100M
YoY Change	-92.31%	-77.09%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$1.206B	$1.213B
YoY Change	-38.05%	-48.57%
LONG-TERM ASSETS
Property, Plant & Equipment	$66.06M	$92.48M
YoY Change	-36.55%	-10.87%
Goodwill	$16.94M	$16.94M
YoY Change	0.0%	0.0%
Intangibles	$18.90M	$22.47M
YoY Change	-26.15%	-31.14%
Long-Term Investments	$280.0M	$359.7M
YoY Change	434.76%	631.34%
Other Assets	$19.66M	$18.92M
YoY Change	-16.69%	-18.76%
Total Long-Term Assets	$463.8M	$580.9M
YoY Change	55.88%	89.02%
TOTAL ASSETS
Total Short-Term Assets	$1.206B	$1.213B
Total Long-Term Assets	$463.8M	$580.9M
Total Assets	$1.670B	$1.794B
YoY Change	-25.59%	-32.71%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$4.389M	$7.114M
YoY Change	-64.5%	-41.44%
Accrued Expenses	$75.32M	$72.26M
YoY Change	-61.88%	-84.15%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$96.41M	$94.07M
YoY Change	-57.27%	-80.62%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$13.86M	$14.24M
YoY Change	14.56%	72.9%
Total Long-Term Liabilities	$13.86M	$14.24M
YoY Change	14.56%	72.9%
TOTAL LIABILITIES
Total Short-Term Liabilities	$96.41M	$94.07M
Total Long-Term Liabilities	$13.86M	$14.24M
Total Liabilities	$235.9M	$246.6M
YoY Change	-45.61%	-64.52%
SHAREHOLDERS EQUITY
Retained Earnings	-$441.5M	-$303.1M
YoY Change	-1162.22%	-228.25%
Common Stock	$14.00K	$14.00K
YoY Change	7.69%	7.69%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$1.434B	$1.547B
YoY Change
Total Liabilities & Shareholders Equity	$1.670B	$1.794B
YoY Change	-25.59%	-32.71%

Cashflow Statement

Concept	2024 Q2	2024 Q1
OPERATING ACTIVITIES
Net Income	-$138.4M	-$65.28M
YoY Change	-28.95%	-53.69%
Depreciation, Depletion And Amortization	$4.200M	$4.517M
YoY Change	-8.7%	-17.87%
Cash From Operating Activities	-$77.85M	-$109.4M
YoY Change	-80.0%	-13.03%
INVESTING ACTIVITIES
Capital Expenditures	$666.0K	$1.872M
YoY Change	-92.96%	-72.74%
Acquisitions
YoY Change
Other Investing Activities	$212.3M	$30.29M
YoY Change	-11.47%	-71.14%
Cash From Investing Activities	$211.6M	$28.42M
YoY Change	-8.12%	-71.02%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	2.942M	$152.0K
YoY Change	-7.46%	-93.52%
NET CHANGE
Cash From Operating Activities	-77.85M	-$109.4M
Cash From Investing Activities	211.6M	$28.42M
Cash From Financing Activities	2.942M	$152.0K
Net Change In Cash	136.7M	-$80.82M
YoY Change	-187.77%	218.7%
FREE CASH FLOW
Cash From Operating Activities	-$77.85M	-$109.4M
Capital Expenditures	$666.0K	$1.872M
Free Cash Flow	-$78.51M	-$111.3M
YoY Change	-80.31%	-16.12%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2024Q1	vir	Equity Investment Current EquityInvestmentCurrent	3927000	usd
CY2023Q4	vir	Equity Investment Current EquityInvestmentCurrent	9853000	usd
CY2024Q1	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	1526000	usd
CY2023Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	1526000	usd
CY2024Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	109171000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	111673000	usd
CY2024Q1	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	27610000	usd
CY2023Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	25960000	usd
CY2024Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	14238000	usd
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	14258000	usd
CY2024Q1	us-gaap	Liabilities Liabilities	246613000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	328824000	usd
CY2024Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2024Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2024Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	134781286	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	134781286	shares
CY2024Q1	us-gaap	Common Stock Value CommonStockValue	14000	usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	13000	usd
CY2024Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1852839000	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1828862000	usd
CY2024Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1547356000	usd
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1590236000	usd
CY2024Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1793969000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1919060000	usd
CY2024Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2024Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2024Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2024Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2024Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-2397000	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-815000	usd
CY2024Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-303100000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-237824000	usd
CY2024Q1	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#AccruedLiabilitiesAndOtherLiabilities
CY2023Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#AccruedLiabilitiesAndOtherLiabilities
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2024Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2024Q1	us-gaap	Revenues Revenues	56376000	usd
CY2023Q1	us-gaap	Revenues Revenues	62957000	usd
CY2024Q1	us-gaap	Cost Of Revenue CostOfRevenue	59000	usd
CY2023Q1	us-gaap	Cost Of Revenue CostOfRevenue	1907000	usd
CY2024Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	100125000	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	157643000	usd
CY2024Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	36273000	usd
CY2023Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	46778000	usd
CY2024Q1	us-gaap	Costs And Expenses CostsAndExpenses	136457000	usd
CY2023Q1	us-gaap	Costs And Expenses CostsAndExpenses	206328000	usd
CY2024Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-80081000	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-143371000	usd
CY2024Q1	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	-5915000	usd
CY2023Q1	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	-13103000	usd
CY2024Q1	us-gaap	Investment Income Net Amortization Of Discount And Premium InvestmentIncomeNetAmortizationOfDiscountAndPremium	21283000	usd
CY2023Q1	us-gaap	Investment Income Net Amortization Of Discount And Premium InvestmentIncomeNetAmortizationOfDiscountAndPremium	21307000	usd
CY2024Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-287000	usd
CY2023Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-8021000	usd
CY2024Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	15081000	usd
CY2023Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	183000	usd
CY2024Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-65000000	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-143188000	usd
CY2024Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	276000	usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-2232000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-65276000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-140956000	usd
CY2024Q1	vir	Net Income Loss Net Of Tax Attributable To Noncontrolling Interest NetIncomeLossNetOfTaxAttributableToNoncontrollingInterest	0	usd
CY2023Q1	vir	Net Income Loss Net Of Tax Attributable To Noncontrolling Interest NetIncomeLossNetOfTaxAttributableToNoncontrollingInterest	-56000	usd
CY2024Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-65276000	usd
CY2023Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-140900000	usd
CY2024Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.48
CY2024Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.48
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.06
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.06
CY2024Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	135280648	shares
CY2024Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	135280648	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	133552839	shares
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	133552839	shares
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-65276000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-140956000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-1411000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	5894000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci Pension And Other Postretirement Benefit Plans For Net Gain Loss Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossNetOfTax	171000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci Pension And Other Postretirement Benefit Plans For Net Gain Loss Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossNetOfTax	-9000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-1582000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	5903000	usd
CY2024Q1	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-66858000	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-135053000	usd
CY2024Q1	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	0	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-56000	usd
CY2024Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-66858000	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-134997000	usd
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1590236000	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	1000	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	220000	usd
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	23757000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-1582000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-65276000	usd
CY2024Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1547356000	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	2077963000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	2310000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	25481000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	5903000	usd
CY2023Q1	vir	Contributions From Noncontrolling Interest Owners ContributionsFromNoncontrollingInterestOwners	100000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-140956000	usd
CY2023Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1970801000	usd
CY2024Q1	us-gaap	Profit Loss ProfitLoss	-65276000	usd
CY2023Q1	us-gaap	Profit Loss ProfitLoss	-140956000	usd
CY2024Q1	vir	Change In Estimated Constraint On Profit Sharing Amount ChangeInEstimatedConstraintOnProfitSharingAmount	685000	usd
CY2023Q1	vir	Change In Estimated Constraint On Profit Sharing Amount ChangeInEstimatedConstraintOnProfitSharingAmount	-31541000	usd
CY2024Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	4517000	usd
CY2023Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	5638000	usd
CY2024Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-238000	usd
CY2023Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	9365000	usd
CY2024Q1	vir	Noncash Lease Expense NoncashLeaseExpense	1447000	usd
CY2023Q1	vir	Noncash Lease Expense NoncashLeaseExpense	2173000	usd
CY2024Q1	us-gaap	Assets Fair Value Adjustment AssetsFairValueAdjustment	5915000	usd
CY2023Q1	us-gaap	Assets Fair Value Adjustment AssetsFairValueAdjustment	13103000	usd
CY2024Q1	vir	Change In Estimated Fair Value Of Contingent Consideration ChangeInEstimatedFairValueOfContingentConsideration	1650000	usd
CY2023Q1	vir	Change In Estimated Fair Value Of Contingent Consideration ChangeInEstimatedFairValueOfContingentConsideration	-1246000	usd
CY2024Q1	us-gaap	Share Based Compensation ShareBasedCompensation	23757000	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	25481000	usd
CY2024Q1	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	-176000	usd
CY2023Q1	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	206000	usd
CY2024Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	401000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-2093000	usd
CY2024Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-1834000	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-9493000	usd
CY2024Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	86000	usd
CY2023Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	1984000	usd
CY2024Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	735000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	6564000	usd
CY2024Q1	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-30003000	usd
CY2023Q1	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-4036000	usd
CY2024Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-4067000	usd
CY2023Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-3105000	usd
CY2024Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-50159000	usd
CY2023Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	1700000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-109390000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-125782000	usd
CY2024Q1	us-gaap	Proceeds From Sale Of Machinery And Equipment ProceedsFromSaleOfMachineryAndEquipment	533000	usd
CY2023Q1	us-gaap	Proceeds From Sale Of Machinery And Equipment ProceedsFromSaleOfMachineryAndEquipment	0	usd
CY2024Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1872000	usd
CY2023Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	6867000	usd
CY2024Q1	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	562939000	usd
CY2023Q1	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	384513000	usd
CY2024Q1	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	592698000	usd
CY2023Q1	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	489459000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	28420000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	98079000	usd
CY2024Q1	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	69000	usd
CY2023Q1	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	66000	usd
CY2024Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	221000	usd
CY2023Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	2310000	usd
CY2024Q1	us-gaap	Proceeds From Minority Shareholders ProceedsFromMinorityShareholders	0	usd
CY2023Q1	us-gaap	Proceeds From Minority Shareholders ProceedsFromMinorityShareholders	100000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	152000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2344000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-80818000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-25359000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	261292000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	867968000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	180474000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	842609000	usd
CY2024Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	160711000	usd
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	824913000	usd
CY2024Q1	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	13335000	usd
CY2023Q1	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	10957000	usd
CY2024Q1	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	6428000	usd
CY2023Q1	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	6739000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	180474000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	842609000	usd
CY2024Q1	vir	Number Of Technology Platforms NumberOfTechnologyPlatforms	2	platform
CY2023Q4	vir	Sale Of Stock Consideration Aggregate Offering Price SaleOfStockConsiderationAggregateOfferingPrice	300000000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	1510000000	usd
CY2024Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the unaudited condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the unaudited condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could materially differ from those estimates.</span></div>
CY2024Q1	vir	Financial Assets Amortized Cost Basis FinancialAssetsAmortizedCostBasis	1489611000	usd
CY2024Q1	vir	Financial Assets Gross Unrealized Holding Gains FinancialAssetsGrossUnrealizedHoldingGains	247000	usd
CY2024Q1	vir	Financial Assets Gross Unrealized Holding Losses FinancialAssetsGrossUnrealizedHoldingLosses	746000	usd
CY2024Q1	vir	Financial Assets Fair Value FinancialAssetsFairValue	1493039000	usd
CY2023Q4	vir	Financial Assets Amortized Cost Basis FinancialAssetsAmortizedCostBasis	1621500000	usd
CY2023Q4	vir	Financial Assets Gross Unrealized Holding Gains FinancialAssetsGrossUnrealizedHoldingGains	1044000	usd
CY2023Q4	vir	Financial Assets Gross Unrealized Holding Losses FinancialAssetsGrossUnrealizedHoldingLosses	130000	usd
CY2023Q4	vir	Financial Assets Fair Value FinancialAssetsFairValue	1632267000	usd
CY2024Q1	us-gaap	Financing Receivable Accrued Interest Writeoff FinancingReceivableAccruedInterestWriteoff	0	usd
CY2023Q1	us-gaap	Financing Receivable Accrued Interest Writeoff FinancingReceivableAccruedInterestWriteoff	0	usd
CY2024Q1	us-gaap	Debt Securities Available For Sale Unrealized Gain Loss DebtSecuritiesAvailableForSaleUnrealizedGainLoss	-500000	usd
CY2023	us-gaap	Debt Securities Available For Sale Unrealized Gain Loss DebtSecuritiesAvailableForSaleUnrealizedGainLoss	900000	usd
CY2024Q1	us-gaap	Other Assets Current OtherAssetsCurrent	4100000	usd
CY2023Q4	us-gaap	Other Assets Current OtherAssetsCurrent	7600000	usd
CY2024Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	130622000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	129914000	usd
CY2024Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	38145000	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	33896000	usd
CY2024Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	92477000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	96018000	usd
CY2024Q1	us-gaap	Depreciation Depreciation	4400000	usd
CY2023Q1	us-gaap	Depreciation Depreciation	5500000	usd
CY2024Q1	vir	Research And Development Expenses Current ResearchAndDevelopmentExpensesCurrent	27314000	usd
CY2023Q4	vir	Research And Development Expenses Current ResearchAndDevelopmentExpensesCurrent	33129000	usd
CY2024Q1	vir	Payroll And Related Expenses Current PayrollAndRelatedExpensesCurrent	17508000	usd
CY2023Q4	vir	Payroll And Related Expenses Current PayrollAndRelatedExpensesCurrent	41322000	usd
CY2024Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	11913000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	12867000	usd
CY2024Q1	vir	Excess Funds Payable Under Grant Agreements Current ExcessFundsPayableUnderGrantAgreementsCurrent	7603000	usd
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.892
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.893
CY2023Q4	vir	Excess Funds Payable Under Grant Agreements Current ExcessFundsPayableUnderGrantAgreementsCurrent	9202000	usd
CY2024Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	3492000	usd
CY2023Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	3418000	usd
CY2024Q1	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	1112000	usd
CY2023Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	816000	usd
CY2024Q1	vir	Profit Share Amount ProfitShareAmount	287000	usd
CY2023Q4	vir	Profit Share Amount ProfitShareAmount	0	usd
CY2024Q1	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	146000	usd
CY2023Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	149000	usd
CY2024Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	2885000	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	3317000	usd
CY2024Q1	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	72260000	usd
CY2023Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	104220000	usd
CY2023Q4	us-gaap	Restructuring And Related Cost Number Of Positions Eliminated RestructuringAndRelatedCostNumberOfPositionsEliminated	75	position
CY2023Q4	us-gaap	Restructuring And Related Cost Number Of Positions Eliminated Period Percent RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent	0.12
CY2023	us-gaap	Severance Costs1 SeveranceCosts1	5900000	usd
CY2023Q4	us-gaap	Restructuring Reserve RestructuringReserve	4500000	usd
CY2023	us-gaap	Asset Impairment Charges AssetImpairmentCharges	7700000	usd
CY2023	us-gaap	Asset Impairment Charges AssetImpairmentCharges	7700000	usd
CY2024Q1	vir	Number Of Directors On Brii Bio Parents Board NumberOfDirectorsOnBriiBioParentsBoard	1	director
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y1M6D
CY2024Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	16540696	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	1.007
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	1.012
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.043
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.034
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.041
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2024Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	23757000	usd
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	25481000	usd
CY2024Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-65276000	usd
CY2023Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-140900000	usd
CY2024Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	135280648	shares
CY2024Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	135280648	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	133552839	shares
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	133552839	shares
CY2024Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.48
CY2024Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.48
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.06
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.06
CY2023Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	12167833	shares
CY2024Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-65000000	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-143188000	usd
CY2024Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	276000	usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-2232000	usd
CY2024Q1	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.004
CY2023Q1	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.016
CY2024Q1	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	13900000	usd
CY2023Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	13600000	usd

Files In Submission

Name	View Source	Status
0001628280-24-020299-index-headers.html	Edgar Link	pending
0001628280-24-020299-index.html	Edgar Link	pending
0001628280-24-020299.txt	Edgar Link	pending
0001628280-24-020299-xbrl.zip	Edgar Link	pending
a20240503-q110qex101.htm	Edgar Link	pending
a20240503-q110qex311.htm	Edgar Link	pending
a20240503-q110qex312.htm	Edgar Link	pending
a20240503-q110qex321.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
vir-20240331.htm	Edgar Link	pending
vir-20240331.xsd	Edgar Link	pending
vir-20240331_def.xml	Edgar Link	unprocessable
vir-20240331_lab.xml	Edgar Link	unprocessable
vir-20240331_pre.xml	Edgar Link	unprocessable
vir-20240331_htm.xml	Edgar Link	completed
vir-20240331_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$VIR
Vir Biotechnology, Inc. Stock $vir

2024 Q2 Form 10-Q Financial Statement

#000162828024020299 Filed on May 03, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$VIR Vir Biotechnology, Inc. Stock $vir

2024 Q2 Form 10-Q Financial Statement

#000162828024020299 Filed on May 03, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$VIR
Vir Biotechnology, Inc. Stock $vir